Cited by 605CAR-T cell therapy researchCancer Immunotherapy and BiomarkersOccupational and environmental lung diseases

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Open access

Adusumilli, Prasad S., Zauderer, Marjorie G., Rivière, Isabelle, Solomon, Stephen B., Rusch, Valerie W., O'Cearbhaill, Roisin E., Zhu, Amy, Cheema, Waseem, Chintala, Navin K., Halton, Elizabeth, Pineda, John, Perez-Johnston, Rocio, Tan, Kay See, Daly, Bobby, Araujo Filho, Jose A., Ngai, Daniel, McGee, Erin, Vincent, Alain, Diamonte, Claudia, Sauter, Jennifer L., Modi, Shanu, Sikder, Devanjan, Senechal, Brigitte, Wang, Xiuyan, Travis, William D., Gönen, Mithat, Rudin, Charles M., Brentjens, Renier J., Jones, David R., Sadelain, Michel·2021·Cancer Discovery

DOI 10.1158/2159-8290.cd-21-0407PMC PMC8563385

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

Malignant pleural diseases, comprising metastatic lung and breast cancers and malignant pleural mesothelioma (MPM), are aggressive solid tumors with poor therapeutic response. We developed and conducted a first-in-human, phase I study of regionally delivered, autologous, mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy. Intrapleural administration of 0.3M to 60M CAR T cells/kg in 27 patients (25 with MPM) was safe and well tolerated. CAR T cells were detected in peripheral blood for >100 days in 39% of patients. Following our demonstration that PD-1 blockade enhances CAR T-cell function in mice, 18 patients with MPM also received pembrolizumab safely. Among those patients, median overall survival from CAR T-cell infusion was 23.9 months (1-year overall survival, 83%). Stable disease was sustained for ≥6 months in 8 patients; 2 exhibited complete metabolic response on PET scan. Combination immunotherapy with CAR T cells and PD-1 blockade agents should be further evaluated in patients with solid tumors. Significance: Regional delivery of mesothelin-targeted CAR T-cell therapy followed by pembrolizumab administration is feasible, safe, and demonstrates evidence of antitumor efficacy in patients with malignant pleural diseases. Our data support the investigation of combination immunotherapy with CAR T cells and PD-1 blockade agents in solid tumors. See related commentary by Aldea et al., p. 2674. This article is highlighted in the In This Issue feature, p. 2659

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-21-0407

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,411
Self-citation
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): A Multicentre, Randomised, Open-Label, Phase 3 Trial
Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32714-8 · Cited by 1,215
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Cherkassky, L., Morello, A., Villena‐Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,098
Self-citation
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J. F., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,062
Self-citation
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial
Zalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01238-6 · Cited by 968
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637
Self-citation
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603
Self-citation

Show all 37 references

Sorted by citations

Items 101–200 of 599

Development of CAR T Cell Therapy in Children—A Comprehensive Overview
Boettcher, M., Joechner, A., Li, Z., Yang, S. F., & Schlegel, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082158 · Cited by 42
Optimizing CAR T cell therapy for solid tumours: a clinical perspective
Li, J., Liu, C., Zhang, P., Shen, L., & Qi, C. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01075-1 · Cited by 41
Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy
Yang, K., Zhao, Y., Sun, G., Zhang, X., Cao, J., Shao, M.-C., Liang, X., & Wang, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1081546 · Cited by 42
Immunomodulatory effect of locoregional therapy in the tumor microenvironment
Xie, L., & Meng, Z. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.017 · Cited by 41
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects
Qin, H., Zhou, Z., Shi, R., Mai, Y., Xu, Y., Fu, P., Cheng, G., Zhang, Z., Chen, W., Chen, Y., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01701-6 · Cited by 43
The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy
Zhang, G., Guanchang, J., Liwen, L., Huifen, W., Zhigang, R., Ranran, S., & Yu, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.918869 · Cited by 39
NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer
Li, J., Hu, H., Lian, H., Yang, S., Liu, M., He, J., Cao, B., Chen, D. S., Hu, Y., Zhi, C., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.88539 · Cited by 39
The potential and promise for clinical application of adoptive T cell therapy in cancer
Li, Y., Zheng, Y., Liu, T., Liao, C., Shen, G., & He, Z. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05206-7 · Cited by 41
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology
Kembuan, G. J., Kim, J. Y., Maus, M. V., & Jan, M. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.01.003 · Cited by 37
The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review
Satapathy, B. P., Sheoran, P., Yadav, R., Chettri, D., Sonowal, D., Dash, C. P., Dhaka, P., Uttam, V., Yadav, R., Jain, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1389971 · Cited by 41
CAR-T-Cell-Based Cancer Immunotherapies: Potentials, Limitations, and Future Prospects
Choudhery, M. S., Arif, T., Mahmood, R., & Harris, D. T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113202 · Cited by 40
TET2 regulates early and late transitions in exhausted CD8 + T cell differentiation and limits CAR T cell function
Dimitri, A. J., Baxter, A. E., Chen, G. M., Hopkins, C. R., Rouin, G. T., Huang, H., Kong, W., Holliday, C., Wiebking, V., Bartoszek, R. L., et al. (2024) · Science Advances · doi:10.1126/sciadv.adp9371 · Cited by 42
Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma
Yeo, D., Castelletti, L., van Zandwijk, N., & Rasko, J. E. J. (2021) · Cancers · doi:10.3390/cancers13163932 · Cited by 37
Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer
Lim, J. U., Lee, E., Lee, S., Cho, H. J., Ahn, D. H., Hwang, Y., Choi, J. Y., Yeo, C. D., Park, C. K., & Kim, S. J. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-633 · Cited by 36
In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies
Chen, Y., Xin, Q., Qiu, J., Zhu, M., Li, Z., Tu, J., Tu, J., & Li, R. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00725-5 · Cited by 36
Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR/Cas9
Amiri, M., Moaveni, A. K., Zolbin, M. M., Shademan, B., & Nourazarian, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1462697 · Cited by 37
Affinity-tuned mesothelin CAR T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity
Yang, Y., Vedvyas, Y., Alcaina, Y., Trumper, S. J., Babu, D. S., Min, I. M., Tremblay, J. M., Shoemaker, C. B., & Jin, M. M. (2024) · JCI Insight · doi:10.1172/jci.insight.186268 · Cited by 37
Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors
Ding, J. P., Guyette, S., Schrand, B., Geirut, J., Horton, H. M., Guo, G., Delgoffe, G. M., Menk, A. V., Baeuerle, P. A., Hofmeister, R., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2182058 · Cited by 35
CAR‐T‐cell products in solid tumors: Progress, challenges, and strategies
Qian, K., Li, G., Zhang, S., Fu, W., Li, T., Zhao, J., Lei, C., Wang, Y., & Hu, S. (2024) · Interdisciplinary medicine · doi:10.1002/inmd.20230047 · Cited by 36
Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors
Laurent, P.-A., Morel, D., Meziani, L., Depil, S., & Deutsch, É. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2158013 · Cited by 34
State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future?
Amorós-Pérez, B., Rivas-Pardo, B., del Moral, M. G., Subiza, J. L., & Martı́nez-Naves, E. (2024) · Cells · doi:10.3390/cells13090725 · Cited by 34
PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response
Tang, O. Y., Tian, L., Yoder, T., Xu, R., Kulikovskaya, I. M., Gupta, M., Melenhorst, J. J., Lacey, S. F., O’Rourke, D. M., & Binder, Z. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.872756 · Cited by 33
Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma
Chintala, N. K., Choe, J. K., McGee, E., Bellis, R. Y., Saini, J. K., Banerjee, S., Moreira, A. L., Zauderer, M. G., Adusumilli, P. S., & Rusch, V. W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1112960 · Cited by 32
Self-citation
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry Perspective
Mody, H. R., Ogasawara, K., Zhu, X., Miles, D., Shastri, P. N., Gokemeijer, J., Liao, M. Z., Kasichayanula, S., Yang, T., Chemuturi, N. V., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2986 · Cited by 34
Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope
Liu, X. F., Onda, M., Schlomer, J., Bassel, L., Kozlov, S., Tai, C., Zhou, Q., Liu, W., Tsao, H., Hassan, R., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2317283121 · Cited by 32
Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial
Ghosn, M., Cheema, W., Zhu, A., Livschitz, J., Maybody, M., Boas, F. E., Santos, E., Kim, D., Beattie, J. A., Offin, M., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.003 · Cited by 32
Self-citation
Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
Ge, Y., Zhang, Y., Zhao, K., & Zhu, H. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s374672 · Cited by 32
Four challenges to CAR T cells breaking the glass ceiling
Bailey, S. R., Berger, T. R., Graham, C., Larson, R. C., & Maus, M. V. (2022) · European Journal of Immunology · doi:10.1002/eji.202250039 · Cited by 34
Cytokine signaling in chimeric antigen receptor T-cell therapy
Kagoya, Y. (2023) · International Immunology · doi:10.1093/intimm/dxad033 · Cited by 31
Adoptive T cell therapy for ovarian cancer
Gitto, S. B., Ihewulezi, C., & Powell, D. J. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.04.001 · Cited by 31
Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies
Haanen, J. B. A. G., Los, C., Phan, G. Q., & Warner, A. B. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_431608 · Cited by 31
Pleural mesothelioma
Fennell, D. A., Sekido, Y., Baas, P., Husain, A. N., Fontecedro, A. C., Lim, E. K. S., Opitz, I., Simone, C. B., Brims, F., & Wong, M. C. S. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00640-3 · Cited by 33
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma
Danlos, F., Texier, M., Job, B., Mouraud, S., Cassard, L., Baldini, C., Varga, A., Yurchenko, A. A., Rabeau, A., Champiat, S., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0886 · Cited by 33
Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture
Li, Y.-R., Zhou, K., Lee, D., Zhu, Y., Halladay, T., Yu, J., Zhou, Y., Lyu, Z., Fang, Y., Chen, Y., et al. (2025) · Nature Protocols · doi:10.1038/s41596-024-01077-w · Cited by 30
The Tmod cellular logic gate as a solution for tumor-selective immunotherapy
DiAndreth, B., Hamburger, A. E., Han, X., & Kamb, A. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109030 · Cited by 30
The effects of electron scattering and wind clumping for early emission line stars
Hillier, D. J. (1991) · Cited by 30
Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer
Hu, C., Liu, M., Li, Y., Zhao, Y., Sharma, A., Liu, H., & Schmidt‐Wolf, I. G. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213716 · Cited by 30
Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy
Quach, H. T., Skovgard, M. S., Villena‐Vargas, J., Bellis, R. Y., Chintala, N. K., Amador-Molina, A., Bai, Y., Banerjee, S., Saini, J. K., Xiong, Y., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0840 · Cited by 31
Self-citation
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy
Shao, W., Yao, Y., Yang, L., Li, X., Ge, T., Zheng, Y., Zhu, Q., Ge, S., Gu, X., Jia, R., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00504-8 · Cited by 30
Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer
Amit, U., Uslu, U., Verginadis, I. I., Kim, M. M., Motlagh, S. A. O., Diffenderfer, E. S., Assenmacher, C., Bicher, S., Atoche, S. J., Ben‐Josef, E., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2403002121 · Cited by 29
Fibroblast activation protein constitutes a novel target of chimeric antigen receptor T‐cell therapy in solid tumors
Meng, S., Hara, T., Miura, Y., & Ishii, H. (2024) · Cancer Science · doi:10.1111/cas.16285 · Cited by 29
New insights into CAR T cell-mediated killing of tumor cells
Espie, D., & Donnadieu, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016208 · Cited by 30
Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
Yoshimoto, S., Chester, N., Xiong, A., Radaelli, E., Wang, H., Brillantes, M., Gulendran, G., Glassman, P. M., Siegel, D. L., & Mason, N. J. (2023) · mAbs · doi:10.1080/19420862.2023.2287250 · Cited by 29
Nanomaterials Boost CAR‐T Therapy for Solid Tumors
Long, J., Wang, Y., Jiang, X., Ge, J., Chen, M., Zheng, B., Wang, R., Wang, M., Xu, M., Qi, K., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304615 · Cited by 28
Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies
Xiang, M., Li, H., Zhan, Y., Ma, D., Gao, Q., & Fang, Y. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01987-z · Cited by 29
mRNA-based therapeutic strategies for cancer treatment
Taibi, T., Cheon, S., Perna, F., & Vu, L. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.035 · Cited by 31
Strategies for Improving CAR T Cell Persistence in Solid Tumors
Wittling, M. C., Cole, A. C., Brammer, B., Diatikar, K. G., Schmitt, N. C., & Paulos, C. M. (2024) · Cancers · doi:10.3390/cancers16162858 · Cited by 31
Present and Future of Immunotherapy for Triple-Negative Breast Cancer
Sriramulu, S., Thoidingjam, S., Speers, C. W., & Nyati, S. (2024) · Cancers · doi:10.3390/cancers16193250 · Cited by 30
Immunotherapies against HER2-Positive Breast Cancer
Duro‐Sánchez, S., Alonso, M. R., & Arribas, J. (2023) · Cancers · doi:10.3390/cancers15041069 · Cited by 29
Coengineering specificity, safety, and function into T cells for cancer immunotherapy
Attianese, G. M. P. G., Ash, S., & Irving, M. B. (2023) · Immunological Reviews · doi:10.1111/imr.13252 · Cited by 29
Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1
Tran, T. M., Thakuri, B. K. C., Nurmukhambetova, S. T., Lee, J., Hu, P., Tran, N. Q., Steimle, B. L., Dash, P., & Schneider, D. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008261 · Cited by 28
Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy
Carcopino, C., Erdogan, E., Henrich, M., & Kobold, S. (2024) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2024.100739 · Cited by 27
Transforming the “cold” tumors to “hot” tumors: strategies for immune activation
Kong, X., Ou, S., Wei, Z., Ye, X., Chen, S., Shi, X., & Zhang, R. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117194 · Cited by 28
PD ‐1: A critical player and target for immune normalization
Liu, X., Zhao, A., Xiao, S., Li, H., Li, M., Guo, W., & Han, Q. (2024) · Immunology · doi:10.1111/imm.13755 · Cited by 27
Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment
Chang, Y., Chang, M., Bao, X., & Dong, C. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.08.046 · Cited by 28
Intraperitoneal infusion of NKG2D CAR-NK cells induces endogenous CD8+ T cell activation in patients with advanced colorectal cancer
Li, B., Zhu, X., Ge, J., Zhang, H., Gao, Y., Bao, X., Dai, X., Du, Z., Tu, X., Zhou, T., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.05.026 · Cited by 26
Barriers and solutions for CAR-T therapy in solid tumors
Tu, Z., Chen, Y., Zhang, Z., Meng, W., & Li, L. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00931-7 · Cited by 32
Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer
Aznar, M. A., Good, C. R., Barber-Rotenberg, J. S., Agarwal, S., Wilson, W. V., Watts, A., Zhang, Z., Gonzales, D. M., Donahue, G., Hwang, W.-T., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102301 · Cited by 30
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma
Tagliamento, M., Bironzo, P., Curcio, H., Luca, E. D., Pignataro, D., Rapetti, S. G., Audisio, M., Bertaglia, V., Paratore, C., Bungaro, M., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103639 · Cited by 26
Emerging Novel Combined CAR-T Cell Therapies
Nguyen, T. A., Johanning, G. L., & Shi, Y. H. (2022) · Cancers · doi:10.3390/cancers14061403 · Cited by 27
Organ-specific heterogeneity in tumor-infiltrating immune cells and cancer antigen expression in primary and autologous metastatic lung adenocarcinoma
Restle, D. J., Dux, J., Li, X., Byun, A. J., Choe, J. K., Li, Y., Vaghjiani, R. G., Thomas, C., Misawa, K., Tan, K. S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006609 · Cited by 26
Self-citation
Cancer Nano-Immunotherapy: The Novel and Promising Weapon to Fight Cancer
García-Domínguez, D. J., López-Enríquez, S., Álba, G., Garnacho, C., Jiménez‐Cortegana, C., Flores-Campos, R., de la Cruz‐Merino, L., Hajji, N., Sánchez‐Margalet, V., & Hontecillas‐Prieto, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021195 · Cited by 26
Challenges in Implementing Comprehensive Precision Medicine Screening for Ovarian Cancer
Moffitt, L. R., Karimnia, N., Wilson, A., Stephens, A. N., Ho, G., & Bilandzic, M. (2024) · Current Oncology · doi:10.3390/curroncol31120592 · Cited by 25
Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors
Zhang, G., Bai, M., Du, H., Yuan, Y., Wang, Y., Fan, W., Zhu, H., Wu, D., He, P., & Xue, B. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s519616 · Cited by 26
Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners
Stock, S., Kluever, A.-K., Endres, S., & Kobold, S. (2022) · Biomedicines · doi:10.3390/biomedicines10020307 · Cited by 25
Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future
Srour, S. A., & Akın, S. (2022) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-7 · Cited by 25
Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications
Mucha, S. R., & Rajendram, P. (2023) · Current Oncology · doi:10.3390/curroncol30050378 · Cited by 26
Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer
Wang, Y., Jiang, C., Zhou, H., & Han, R. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00705-9 · Cited by 25
Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cells
Yagel, G., Rimini, D., von Locquenghien, M., Avellino, R., Barboy, O., Chalan, P., Granot, G., Xie, K., Shlomi-Loubaton, S., Sheban, F., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.11.009 · Cited by 25
An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma
Davis, A. P., Ke, H., Kao, S., & Pavlakis, N. (2022) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s288535 · Cited by 24
Implications for Immunotherapy of Breast Cancer by Understanding the Microenvironment of a Solid Tumor
Franzén, A. S., Raftery, M. J., & Pecher, G. (2022) · Cancers · doi:10.3390/cancers14133178 · Cited by 24
Enhancing personalized immune checkpoint therapy by immune archetyping and pharmacological targeting
Cerella, C., Dicato, M. A., & Diederich, M. F. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106914 · Cited by 24
In vivo programmed myeloid cells expressing novel chimeric antigen receptors show potent anti-tumor activity in preclinical solid tumor models
Argueta, S., Wang, Y., Zhao, H., Diwanji, N., Gorgievski, M., Cochran, E. L., Grudzien‐Nogalska, E., D’Alessandro, J. S., McCreedy, B. J., Prod’homme, T., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1501365 · Cited by 26
Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy
Lucia, A. D., Mazzotti, L., Gaimari, A., Zurlo, M., Maltoni, R., Cerchione, C., Bravaccini, S., Delmonte, A., Crinò, L., de Souza, P. B., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1515748 · Cited by 25
Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression
Aboalela, M. A., Abdelmoneim, M., Matsumura, S., Eissa, I. R., Bustos‐Villalobos, I., Sibal, P. A., Orikono, Y., Takido, Y., Naoe, Y., & Kasuya, H. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04039-7 · Cited by 23
Magnetic Nanodroplets for Enhanced Deep Penetration of Solid Tumors and Simultaneous Magnetothermal‐Sensitized Immunotherapy against Tumor Proliferation and Metastasis
Wang, J., Zhang, W., Xie, Z., Wang, X., Luo, Y., Jiang, W., Liu, Y., Wang, Z., Ran, H., Song, W., et al. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202201399 · Cited by 23
Self-citation
Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors
Boccalatte, F. E., Mina, R., Aroldi, A., Leone, S., Suryadevara, C. M., Placantonakis, D. G., & Bruno, B. (2022) · Cancers · doi:10.3390/cancers14205108 · Cited by 24
Genome Editing in Engineered T Cells for Cancer Immunotherapy
Bonini, C., Chapuis, A. G., Hudecek, M., Guedan, S., Magnani, C. F., & Qasim, W. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.128 · Cited by 29
Current Trends and Innovative Approaches in Cancer Immunotherapy
Kim, J.-C., Maharjan, R., & Park, J. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02883-x · Cited by 25
CAR T cells secreting NGF-neutralizing scFv enhance efficacy in clear cell renal cell carcinoma by relieving immunosuppression through immunosympathectomy
Yang, P., Chen, X., Fan, Y., Wang, L., Li, M., Bai, Z., & Xu, H. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009910 · Cited by 22
Anti-Mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer
Kutle, I., Polten, R., Stalp, J. L., Hachenberg, J., Todzey, F., Hass, R., Zimmermann, K., von der Ohe, J., von Kaisenberg, C., Neubert, L., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1485461 · Cited by 24
From Multi‐Omics to Visualization and Beyond: Bridging Micro and Macro Insights in CAR‐T Cell Therapy
Gong, Y., Fei, P., Zhang, Y., Xu, Y., & Wei, J. (2025) · Advanced Science · doi:10.1002/advs.202501095 · Cited by 25
Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time
Salas‐Benito, D., Birocchi, F., Park, S., Ho, C. E., Armstrong, A., Parker, A., Bouffard, A. A., Frank, J. A., Kim, E., Kienka, T., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012822 · Cited by 22
Engineering CAR‐T Therapeutics for Enhanced Solid Tumor Targeting
Zhu, D., Kim, W., Lee, H., Bao, X., & Kim, P. (2025) · Advanced Materials · doi:10.1002/adma.202414882 · Cited by 24
CAR Based Immunotherapy of Solid Tumours—A Clinically Based Review of Target Antigens
Maher, J. F., & Davies, D. M. (2023) · Biology · doi:10.3390/biology12020287 · Cited by 21
Adoptive T Cell Therapy in Solid Tumors: State-of-the Art, Current Challenges, and Upcoming Improvements
Dougé, A., El-Ghazzi, N., Lemal, R., & Rouzaire, P. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0310 · Cited by 21
Universal CAR 2.0 to overcome current limitations in CAR therapy
Schlegel, L. S., Werbrouck, C., Boettcher, M., & Schlegel, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1383894 · Cited by 21
Mesothelin-targeted CAR-T cells secreting NKG2D-BiTEs exhibit potent efficacy against triple-negative breast cancer
Saliu, M. A., Wang, Q., Salisu, M. D., Ren, Y., Zhang, P., Suleiman, R. B., Cao, B., Xu, Y., Liu, X., Lluı́s, F., et al. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00621-y · Cited by 20
Spatiotemporal dynamics of tumor–CAR T-cell interaction following local administration in solid cancers
Owens, K. L., Rahman, A., & Božić, I. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013117 · Cited by 20
Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors
Nash, A., Aghlara-Fotovat, S., Castillio, B., Hernández, A., Pugazenthi, A., Lee, H., Jang, H.-J., Nguyen, A., Lu, A., Burt, B. M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1493 · Cited by 20
Theranostic chimeric antigen receptor (CAR)-T cells: Insight into recent trends and challenges in solid tumors
Kheyrolahzadeh, K., Tohidkia, M. R., Tarighatnia, A., Shahabi, P., Nader, N. D., & Aghanejad, A. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121917 · Cited by 20
Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors
Holtermann, A., Gislon, M., Angele, M. K., Subklewe, M. S., von Bergwelt‐Baildon, M., Lauber, K., & Kobold, S. (2024) · BioDrugs · doi:10.1007/s40259-024-00669-y · Cited by 21
Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors
Zhong, W., Qin, Z., Yu, Z., Yang, J., Yan, D., Engel, N. W., Sheppard, N. C., Yi, F., Radhakrishnan, R., Xu, X., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00949-8 · Cited by 19
Novel and Future Treatment Options in Mesothelioma: A Systematic Review
Štrbac, D., & Dolžan, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23041975 · Cited by 19
Intratumoral Immunotherapy: Is It Ready for Prime Time?
Ghosn, M., Tselikas, L., Champiat, S., Deschamps, F., Bonnet, B., Carre, É., Testan, M., Danlos, F., Farhane, S., Susini, S., et al. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01422-4 · Cited by 19
c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation
Xiong, Y., Taleb, M., Misawa, K., Hou, Z., Banerjee, S., Amador-Molina, A., Jones, D. R., Chintala, N. K., & Adusumilli, P. S. (2023) · Nature Cancer · doi:10.1038/s43018-023-00573-4 · Cited by 19
Self-citation
Diffuse Pleural Mesothelioma: Advances in Molecular Pathogenesis, Diagnosis, and Treatment
Febres‐Aldana, C. A., Fanaroff, R. E., Offin, M. D., Zauderer, M. G., Sauter, J. L., Yang, S., & Ladanyi, M. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-042420-092719 · Cited by 20
Self-citation
Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study
Qian, S., Chen, J., Zhao, Y., Zhu, X., Dai, D., Qin, L., Hong, J., Xu, Y., Yang, Z., Li, Y., et al. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.10.007 · Cited by 19
Breaking barriers: advancing cellular therapies in autoimmune disease management
Fu, Y., Feng, C., Qin, S., Xing, Z., Liu, C., Liu, Z., & Yu, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1503099 · Cited by 20
Combinational CAR T-cell therapy for solid tumors: Requisites, rationales, and trials
Misawa, K., Bhat, H., Adusumilli, P. S., & Hou, Z. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108763 · Cited by 20
Self-citation

Authors: Adusumilli, P. S., Zauderer, M. G., Rivière, I., Solomon, S. B., Rusch, V. W., O'Cearbhaill, R. E., Zhu, A., Cheema, W., Chintala, N. K., Halton, E., Pineda, J., Perez-Johnston, R., Tan, K. S., Daly, B., Araujo Filho, J. A., Ngai, D., McGee, E., Vincent, A., Diamonte, C., Sauter, J. L., Modi, S., Sikder, D., Senechal, B., Wang, X., Travis, W. D., Gönen, M., Rudin, C. M., Brentjens, R. J., Jones, D. R., & Sadelain, M.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
6Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
5Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
Corresponding author: Adusumilli, Prasad S.
ORCID: Adusumilli, Prasad S.
Zauderer, Marjorie G.
Rivière, Isabelle
Solomon, Stephen B.
Rusch, Valerie W.
O'Cearbhaill, Roisin E.
Cheema, Waseem
Chintala, Navin K.
Pineda, John
Perez-Johnston, Rocio
Tan, Kay See
Daly, Bobby
Sauter, Jennifer L.
Modi, Shanu
Wang, Xiuyan
Travis, William D.
Gönen, Mithat
Rudin, Charles M.
Brentjens, Renier J.
Jones, David R.
Sadelain, Michel
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2021-07-15
Volume: 11
Issue: 11
Pages: 2748-2763
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-21-0407
PMC: PMC8563385
OpenAlex: W3179214161
Cited by: 605
References: 37
Citations by year: 2026: 124 · 2025: 119 · 2024: 131 · 2023: 125 · 2022: 90 · 2021: 15
FWCI: 32.88
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: NIH (P30 CA008748, R01 CA236615-01, R01 CA235667)
U.S. Department of Defense (BC132124, LC160212, CA180889)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords: mesothelin, chimeric antigen receptor T cells, CAR T-cell therapy, malignant pleural mesothelioma, malignant pleural effusion, pembrolizumab, anti-PD-1 therapy, intrapleural administration, combination immunotherapy, autologous T cells, safety and tolerability, overall survival
MeSH terms: Mesothelin, Humans, Mesothelioma, Pleural Diseases, Immunotherapy, Adoptive, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks